» Articles » PMID: 38505276

Cardiovascular Consequences of Sickle Cell Disease

Overview
Specialty Biophysics
Date 2024 Mar 20
PMID 38505276
Authors
Affiliations
Soon will be listed here.
Abstract

Sickle cell disease (SCD) is an inherited blood disorder caused by a single point mutation within the beta globin gene. As a result of this mutation, hemoglobin polymerizes under low oxygen conditions causing red blood cells to deform, become more adhesive, and increase in rigidity, which affects blood flow dynamics. This process leads to enhanced red blood cell interactions with the endothelium and contributes to vaso-occlusion formation. Although traditionally defined as a red blood cell disorder, individuals with SCD are affected by numerous clinical consequences including stroke, painful crisis episodes, bone infarctions, and several organ-specific complications. Elevated cardiac output, endothelium activation along with the sickling process, and the vaso-occlusion events pose strains on the cardiovascular system. We will present a review of the cardiovascular consequences of sickle cell disease and show connections with the vasculopathy related to SCD. We will also highlight biophysical properties and engineering tools that have been used to characterize the disease. Finally, we will discuss therapies for SCD and potential implications on SCD cardiomyopathy.

Citing Articles

Increased Adhesiveness of Blood Cells Induced by Mercury Chloride: Protective Effect of Hydroxytyrosol.

Perrone P, Ortega-Luna R, Manna C, Alvarez-Ribelles A, Collado-Diaz V Antioxidants (Basel). 2025; 13(12.

PMID: 39765902 PMC: 11673208. DOI: 10.3390/antiox13121576.


Electrocardiographic findings in patients with sickle cell disease: A protocol for systematic review and meta-analysis.

Sadeghi A, Taherifard E, Movahed H, Ahmadkhani A, Dehdari Ebrahimi N, Taherifard E Health Sci Rep. 2024; 7(6):e2212.

PMID: 38915361 PMC: 11194293. DOI: 10.1002/hsr2.2212.

References
1.
Noomuna P, Risinger M, Zhou S, Seu K, Man Y, An R . Inhibition of Band 3 tyrosine phosphorylation: a new mechanism for treatment of sickle cell disease. Br J Haematol. 2020; 190(4):599-609. PMC: 7606656. DOI: 10.1111/bjh.16671. View

2.
Ansari J, Gavins F . Ischemia-Reperfusion Injury in Sickle Cell Disease: From Basics to Therapeutics. Am J Pathol. 2019; 189(4):706-718. PMC: 6446225. DOI: 10.1016/j.ajpath.2018.12.012. View

3.
Podduturi V, Guileyardo J . Sickle cell trait as a contributory cause of death in natural disease. J Forensic Sci. 2015; 60(3):807-11. DOI: 10.1111/1556-4029.12713. View

4.
Akohoue S, Shankar S, Milne G, Morrow J, Chen K, Ajayi W . Energy expenditure, inflammation, and oxidative stress in steady-state adolescents with sickle cell anemia. Pediatr Res. 2007; 61(2):233-8. DOI: 10.1203/pdr.0b013e31802d7754. View

5.
Gerry J, Baird M, Fortuin N . Evaluation of left ventricular function in patients with sickle cell anemia. Am J Med. 1976; 60(7):968-72. DOI: 10.1016/0002-9343(76)90568-4. View